Direkt zum Inhalt
Merck

SML2382

Sigma-Aldrich

SC75741

≥97% (HPLC)

Synonym(e):

4SC-301, N-(5-Benzoyl-1H-benzimidazol-2-yl)-2-(1-thieno[3,2-d]pyrimidin-4-yl-4-piperidinyl)-4-thiazolecarboxamide, N-(6-Benzoyl-1H-benzimidazol-2-yl)-2-(1-thieno[3,2-d]pyrimidin-4-yl-4-piperidinyl)-4-thiazolecarboxamide, SC 75741, V1810

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise


About This Item

Empirische Formel (Hill-System):
C29H23N7O2S2
CAS-Nummer:
Molekulargewicht:
565.67
UNSPSC-Code:
12352200

Assay

≥97% (HPLC)

Form

powder

Farbe

white to beige

Löslichkeit

DMSO: 2 mg/mL, clear

Lagertemp.

2-8°C

SMILES String

O=C(C1=CSC(C2CCN(C3=C4C(C=CS4)=NC=N3)CC2)=N1)NC5=NC6=CC(C(C7=CC=CC=C7)=O)=CC=C6N5

InChI

1S/C29H23N7O2S2/c37-24(17-4-2-1-3-5-17)19-6-7-20-22(14-19)34-29(33-20)35-27(38)23-15-40-28(32-23)18-8-11-36(12-9-18)26-25-21(10-13-39-25)30-16-31-26/h1-7,10,13-16,18H,8-9,11-12H2,(H2,33,34,35,38)

InChIKey

QNZVBFMXWNWVKG-UHFFFAOYSA-N

Biochem./physiol. Wirkung

NF-κB p65 subunit (RelA) DNA-binding inhibitor that effectively blocks influenza virus propagation both in cultures and in mice in vivo.
SC75741 (4SC-301; V1810) is a potent NF-kappaB (NF-κB) inhibitor (IC50 = 200 nM against 10 ng/mL TNF-α-induced NF-κB reporter gene expression in A549 cells) that impairs p65 subunit (RelA) DNA-binding activity without affecting p65 phosphorylation or nuclear translocation, nor proteasome-mediated IκBα degradation. SC75741 induces apoptosis in multiple myeloma cultures (IC50 from 5 to 12 μM in 48 hrs; OPM2, U266, NCI-H929, RPMI-8226), but not PBMCs (89% viability post 4-hr 100 μM SC75741 treatment). NF-κB inhibition by SC75741 treatment is reported to effectively block influenza virus propagation both in cultures in vitro (1-5 μM) and in mice in vivo (5 mg/kg daily i.v. or 7.5-15 mg/kg twice a day i.p.).

Lagerklassenschlüssel

11 - Combustible Solids

WGK

WGK 3

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable


Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Dokumente section.

Wenn Sie Hilfe benötigen, wenden Sie sich bitte an Kundensupport

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Johann Leban et al.
Bioorganic & medicinal chemistry letters, 17(21), 5858-5862 (2007-09-18)
A novel class of NF-kappaB pathway signaling inhibitors was discovered by virtual screening, medicinal chemistry, and QSAR analysis. An initial set of compounds inhibited NF-kappaB signaling in a whole cell reporter gene assay in the micro-molar range. Activity was improved
Emanuel Haasbach et al.
Antiviral research, 99(3), 336-344 (2013-07-03)
The appearance of pandemic H1N1 and highly pathogenic avian H5N1 viruses in humans as well as the emergence of seasonal H1N1 variants resistant against neuraminidase inhibitors highlight the urgent need for new and amply available antiviral drugs. We and others
Christina Ehrhardt et al.
Cellular microbiology, 15(7), 1198-1211 (2013-01-17)
Ongoing human infections with highly pathogenic avian H5N1 viruses and the emergence of the pandemic swine-origin influenza viruses (IV) highlight the permanent threat elicited by these pathogens. Occurrence of resistant seasonal and pandemic strains against the currently licensed antiviral medications
Ke-Wang Luo et al.
The Journal of nutritional biochemistry, 41, 56-64 (2017-01-04)
Epigallocatechin-3-gallate (EGCG), the bioactive polyphenol in green tea, has been demonstrated to have various biological activities. Our study aims to investigate the antiproliferation and antimigration effects of EGCG against bladder cancer SW780 cells both in vitro and in vivo. Our
Felix G Meinel et al.
Molecular cancer therapeutics, 9(2), 300-310 (2010-02-04)
Evidence is increasing that aberrant NF-kappaB activation is crucial for multiple myeloma pathophysiology and a promising target for new antimyeloma therapies. In this study, we assessed the in vitro antimyeloma activity of the novel NF-kappaB inhibitor V1810. Pharmacokinetics and toxicity

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.